CAS 274901-16-5 Purity ≥99.0% (HPLC) API
Manufacturer Supply Related Intermediates:
CAS: 274901-16-5
3-Amino-1-Adamantanol CAS: 702-82-9
L-Prolinamide CAS: 7531-52-4
Boc-L-Proline CAS: 15761-39-4
(2S)-1-(Chloroacetyl)-2-Pyrrolidinecarbonitrile CAS: 207557-35-5
| Synonyms | LAF-237 |
| CAS Number | 274901-16-5 |
| CAT Number | RF-API30 |
| Stock Status | In Stock, Production Scale Up to Hundreds of Kilograms |
| Molecular Formula | C17H25N3O2 |
| Molecular Weight | 303.4 |
| Brand | Ruifu Chemical |
| Item | Specifications |
| Appearance | White Crystalline Powder |
| Identification | IR, HPLC: Must Conform to The Reference Standard |
| Specific Optical Rotation | -82.0° to -92.0° |
| Melting Point | 148.0~152.0℃ |
| Loss on Drying | ≤0.50% |
| Residue on Ignition | ≤0.10% |
| Heavy Metals | ≤20ppm |
| Sulphate | ≤0.02% |
| Chloride | ≤0.05% |
| Chiral Impurity | R-Isomer Impurity ≤0.50% |
| Residual Solvents | |
| Acetonitrile | ≤410ppm |
| Dichloromethane | ≤600ppm |
| Isopropyl Alcohol | ≤5000ppm |
| Related Impurities | By HPLC |
| Impurity A | ≤0.15% |
| Impurity B | ≤0.15% |
| Impurity C | ≤0.20% |
| Other Single Impurity | ≤0.10% |
| Total Impurities | ≤1.00% |
| Purity / Analysis Method | ≥99.0% (HPLC) |
| Test Standard | Enterprise Standard |
| Usage | API, Type 2 Diabetes Mellitus (T2DM) |
Package: Bottle, Aluminum foil bag, 25kg/Cardboard Drum, or according to customer's requirement
Storage Condition: Store in sealed containers at cool and dry place; Protect from light, moisture
Shanghai Ruifu Chemical Co., Ltd. is the leading manufacturer and supplier of API (CAS: 274901-16-5) with high quality. API (CAS: 274901-16-5) is an oral anti-hyperglycemic agent (anti-diabetic drug) of the new dipeptidyl peptidase-4 (DPP-4) inhibitor class of drugs. It was developed by Novartis (Novartis) Pharmaceutical Co., Ltd, is another oral administrated inhibitor of Dipeptidyl peptidase-IV. In 2008, it is approved for marketing in the European Union for the treatment of type 2 diabetes. API (CAS: 274901-16-5) inhibits the inactivation of GLP-1 and GIP by DPP-4, allowing GLP-1 and GIP to potentiate the secretion of insulin in the beta cells and suppress glucagon release by the alpha cells of the islets of Langerhans in the pancreas. API (CAS: 274901-16-5) has been shown to reduce hyperglycemia in type 2 diabetes mellitus.
